Medicago announces presentation at the World Vaccine Congress Asia 2009

    QUEBEC CITY, June 8 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"), a
biotechnology company focused on developing highly effective and affordable
vaccines based on proprietary manufacturing technologies and Virus-Like
Particles (VLPs), today announced that Mr. Andy Sheldon, President and CEO,
presented at the World Vaccine Congress Asia 2009. The conference is being
held at the Marina Mandarin, Singapore, from June 8-11, 2009.
    Mr. Sheldon's presentation, entitled "Innovative H5N1 virus-like
particles: a unique combination of product and manufacturing solutions",
discussed how Medicago's plant-based Proficia(TM) manufacturing technology, a
system that combined with the Company's VLP vaccine technology, could deliver
a vaccine just one month after the identification of the genetic sequence from
an emerging pandemic strain. Mr. Sheldon also reviewed the ongoing research
and development of a H1N1 vaccine candidate. The Company recently disclosed
that it successfully expressed a new VLP antigen ("H1 VLP") from the influenza
A (H1N1) strain within 14 days of receiving the DNA sequence and is currently
conducting a study in mice to determine the immunogenic potential of this new
    World Vaccine Congress Asia 2009 is a meeting where vaccine buyers and
sellers, health authorities, financing institutions, regulators, vaccine
producers and manufacturers, technology providers and other stakeholders come
together to discuss industry trend, market and partnership opportunities, new
vaccines and new technology innovations across Asia.

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at

    Forward-Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release

    %SEDAR: 00023641E

For further information:

For further information: Medicago Inc., Andy Sheldon, President and CEO
Director, (418) 658-9393; Medicago Inc., Arianna Vanin, Investor Relations,
(514) 796-3993

Organization Profile

Medicago Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890